Zai Lab’s Zoci Combination Achieves 81.8% Response Rate in First-Line Lung Cancer Trial
Bitget2026/10/23 10:33- Zai Lab reported encouraging responses with zocilurtatug pelitecan combined with atezolizumab in a Phase 1b trial for first-line extensive-stage small cell lung cancer.
- The platinum-free combination showed durable responses and was generally well tolerated; adding carboplatin led to more frequent severe adverse events.
- Results will be presented at the European Society for Medical Oncology Congress on October 26, 2026.
- A global randomized Phase 3 trial evaluating zocilurtatug pelitecan with an immuno-oncology regimen is expected to begin by year-end 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A net loss of approximately $555,000 has occurred due to the TENDRIL sell mechanism vulnerability.
UBS cuts around 200 positions in London as Credit Suisse integration enters final stage
UBS has recently implemented a new round of staff reductions in London, cutting around 200 positions over the past few weeks. The bank's integration of Credit Suisse is nearing completion.
Wall Street veteran Yardeni: Cooling inflation is expected, 5% US Treasury bonds are "very attractive"
Ed Yardeni, President of Yardeni Research, stated that with inflation expected to cool down, the yield on the 10-year US Treasury at around 5% looks "very attractive."
Crypto prices
More
